Company / R&D per Share
ARS Pharmaceuticals, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.13
FY2025
5-year range
$0.13 / $0.70
FY2021-FY2025
Trend
-33.7%
vs FY2024
Sector context
#198 of 208
Health Care
What the data says
Among 208 Health Care companies, ARS Pharmaceuticals, Inc. is in the bottom 5% for r&d per share. R&D per Share has declined for 5 consecutive years, from $8.45 in FY2020 to $0.13 in FY2025.
Based on SEC 10-K filings.
0.13 in FY2025 with a 5-year CAGR of -56.3%.
Declined from $0.22 to $0.13 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -41.4%
- 5-Year CAGR
- -56.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 208This company $0.13 Sector average $28.82
▼
-99.5% below sector average
Key checks
Key Insights
- ARS Pharmaceuticals, Inc.'s r&d per share has declined for 5 consecutive years.
- In FY2025, r&d per share decreased 33.7% year-over-year.
- Ranks #198 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.13 | -33.7% |
| FY2024 | $0.20 | -5.9% |
| FY2023 | $0.22 | -67.7% |
| FY2022 | $0.67 | -4.9% |
| FY2021 | $0.70 | -91.7% |
| FY2020 | $8.45 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026